Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/17277Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Zygogianni, A. G. | en |
| dc.contributor.author | Kyrgias, G. | en |
| dc.contributor.author | Psyrri, A. | en |
| dc.contributor.author | Kantzou, I. | en |
| dc.contributor.author | Koumarianou, A. | en |
| dc.contributor.author | Tolia, M. | en |
| dc.contributor.author | Tsekeris, P. | en |
| dc.contributor.author | Tsirigotis, P. | en |
| dc.contributor.author | Sarris, G. | en |
| dc.contributor.author | Kouvaris, J. | en |
| dc.contributor.author | Kouloulias, V. | en |
| dc.date.accessioned | 2015-11-24T18:38:06Z | - |
| dc.date.available | 2015-11-24T18:38:06Z | - |
| dc.identifier.issn | 1107-0625 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/17277 | - |
| dc.rights | Default Licence | - |
| dc.subject | chemotherapy | en |
| dc.subject | hodgkin's lymphoma | en |
| dc.subject | new agents | en |
| dc.subject | radiotherapy | en |
| dc.subject | stem-cell-transplantation | en |
| dc.subject | high-dose chemotherapy | en |
| dc.subject | involved-field radiotherapy | en |
| dc.subject | intensity-modulated radiotherapy | en |
| dc.subject | bone-marrow transplantation | en |
| dc.subject | combined-modality therapy | en |
| dc.subject | radiation-therapy | en |
| dc.subject | conventional chemotherapy | en |
| dc.subject | randomized trial | en |
| dc.subject | clinical-trials | en |
| dc.title | Radiotherapy for Hodgkin's lymphoma: too hard to die? | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | <Go to ISI>://000302503700019 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιών | el |
| heal.publicationDate | 2012 | - |
| heal.abstract | The treatment of Hodgkin's lymphoma (HL) is associated with significant toxicity. The objective of high quality management is to keep the concept of combined modality, while trying to decrease the radiation dose, to diminish to a great extent the irradiated volume and at the same time to reduce the number of chemotherapy courses, introducing the so-called optimisation. New directives should be followed to obtain more effective treatments of HL. Shorter cycles of chemotherapy and the utilization of modern techniques in radiotherapy (RT) constitute fundamental steps to achieve this objective. Analysis of randomized studies supports the inclusion of reduced-field and dose of RT in the radiotherapeutic treatment options for HL. RT is an integral part of the combined-modality therapy (CMT) of HL. | en |
| heal.journalName | Journal of Buon | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
